2024
Disorders due to Substance Use: Stimulants
Sevarino K, Farrell M. Disorders due to Substance Use: Stimulants. 2024, 2843-2932. DOI: 10.1007/978-3-030-51366-5_26.Peer-Reviewed Original ResearchBody of preclinical researchAssociated with significant impairmentStimulant use disorderFDA-approved medicationsBehavioral therapyOccupational functioningUse disorderPrescribed stimulantsSignificant impairmentHepatitis CClinical featuresSubstance usePharmacological therapyMedical illnessPreclinical researchRates of overdose deathsCardiovascular diseaseDisordersElevated ratesElevated riskTherapyPotential targetOverdose deathsStimulationAdverse consequences
2023
Disorders Due to Substance Use: Stimulants
Sevarino K, Farrell M. Disorders Due to Substance Use: Stimulants. 2023, 1-90. DOI: 10.1007/978-3-030-42825-9_26-1.Peer-Reviewed Original ResearchBody of preclinical researchAssociated with significant impairmentStimulant use disorderFDA-approved medicationsBehavioral therapyOccupational functioningUse disorderPrescribed stimulantsSignificant impairmentHepatitis CClinical featuresSubstance usePharmacological therapyMedical illnessPreclinical researchRates of overdose deathsCardiovascular diseaseDisordersElevated ratesElevated riskTherapyPotential targetOverdose deathsStimulationAdverse consequences
2015
Stimulant Use Disorders
Sevarino K, Shelby B. Stimulant Use Disorders. 2015, 1561-1614. DOI: 10.1002/9781118753378.ch80.Peer-Reviewed Original ResearchStimulant use disorderUse disordersMonths of treatmentOngoing psychosocial stressorsSubstance abuse treatmentCocaine use disorderDisease courseAcute cravingAppropriate treatmentHigh riskPsychosocial stressorsAbuse treatmentNonmedical useCrystal methamphetamineDrug abuseDisordersMethamphetamineTreatmentPrescription stimulantsAmphetamineStimulantsPatientsRelapseDextroamphetamineMethylphenidate